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A 29-year-old woman with HIV infection was
admitted to our hospital in July 2001 with a history
of headache, vomiting, fever, seizure and weak-
ness of the right side. HIV infection had been diag-
nosed and antiretroviral therapy with zidovudine,
lamivudine and nevirapine had been initiated one
month before admission. Neurological examination
revealed that she had cerebellar dysarthria, mild
dysmetria, dysdiadokokinesis and intention tremor
of the right hand. She had right upper motor neu-
rone-type facial palsy. Neck stiffness was not pre-
sent and the fundi showed no papilloedema but
cotton wool spots were seen bilaterally. The rest
of the systemic examination was within normal
limits. Cranial MRI showed four mass lesions which
gave high signals on T2 weighted images. One lesion
was located in the right cerebellar hemisphere, two
were in the left occipital region and one was in the
left parietal region. They were localized in the
cortex and were 10—155 mm (Figure 1). The lesions
had a region of peripheral edema and the possibility
of toxoplasma encephalitis was suggested. Empiri-
cal anti-toxoplasmosis therapy was started with
intravenous clindamycin (600 mg q6h) because the
patient was allergic to sulfonamides. Antiretroviral
therapy with zidovudine, lamivudine and nevirapine
was continued. Serological investigation for Toxo-
plasma gondiiwith EIA was performed and while IgM
antibodies to T. gondii were negative, the IgG anti-
body level was >300 IU/ml. The patient’s CD4 Tcell
count was 25/mm3 and the ratio of CD4 to CD8 was
0.23. The PPD test was anergic and prophylaxis for
tuberculosis with isoniazid was started. HIV viral
load was >750,000 copies/ml.
Intravenous clindamycin therapy was continued
for 30 days. In this period all neurological signs
except tremor disappeared. At the end of this per-
iod, therapy was changed to oral clindamycin at the
same dosage (600 mg q6h). Two months later, cra-
nial MRI showed that the lesion in the right cere-
bellar hemisphere and the peripheral edema of the
other lesions had disappeared. Clinical signs1201-9712/$30.00 # 2004 International Society for Infectious Diseas
doi:10.1016/j.ijid.2004.05.004resolved completely. HIV viral load was 9776
copies/ml, CD4 cell count was 131/mm3 and the
ratio of CD4/CD8 was 0.41. Serological tests for T.
gondii were performed again and they were
unchanged. Clindamycin dosage was decreased to
1800 mg daily. In the tenthmonth of therapy, cranial
MRI showed no lesions and the patient continued for
two years with 900 mg of clindamycin daily. She had
no signs or symptoms of encephalitis and her HIV
viral load was <50 copies/ml. She is still under
follow-up and she takes clindamycin capsules
(150 mg) three times a day.
Although toxoplasmosis is usually a self-limited
infection, in immunocompromised individuals it
may be life-threatening.1,2 The incidence of cere-
bral toxoplasmosis among patients with HIV infec-
tion varies from 5—40%3—5 and toxoplasmosis is the
most common cause of intracranial mass lesions in
patients with AIDS, accounting for 50—70% of all
mass lesions in this population. More than 95% of
these cases are due to reactivation of a chronic
latent infection.2,5—7 The mainstay of treatment for
toxoplasma encephalitis is combination therapy.
The agents of choice are sulfadiazine with pyri-
methamine; patients who are unable to tolerate
sulfonamides can be treated with a combination of
clindamycin and pyrimethamine.2,5,8,9 Therapy in
this patient was started with clindamycin alone
because the patient was allergic to sulfonamides
and pyrimethamine is not available for therapeutic
use in Turkey. According to the literature no case
has been treated successfully with clindamycin
alone. Roemer et al.9 used clindamycin
(2400 mg/d) to treat a patient with cerebral tox-
oplasmosis but the disease progressed rapidly and
the patient died. The relative efficacy of pyri-
methamine—clindamycin combination therapy was
shown to be equal to that of pyrimethamine—sul-
fadiazine in a randomized clinical trial,10 but
potential use of clindamycin as a single agent has
not been established.8 In a murine toxoplasmosis
model, Nikolic et al. showed that survival rates and
survival times of infected animals increased in
parallel with the clindamycin dosage and treatment
duration. The authors observed that a three-week
treatment course with 50 mg/kg per day was betteres. Published by Elsevier Ltd. All rights reserved.
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Figure 1 T2 weighted images of the patient at the time
of admission.than a dosage eight times higher given for a shorter
period.11 Gatti et al.3 found that clindamycin con-
centrations in CSF were several times higher than
the parasiticidal concentration and they suggested
combination therapy with pyrimethamine because
of the synergistic activity of these two agents. For
maintenance treatment of HIV-infected patients,
continuation of the acute therapeutic regimen is
suggested.2,5,8
In AIDS patients with toxoplasma encephalitis,
radiological improvement is seen in most of the
patients after two to three weeks of treatment.
Complete resolution takes from six weeks to sixmonths.2 In the patient reported here, brain lesions
resolved very slowly and at the second month of
therapy one of the lesions had disappeared and
clinical signs had resolved completely. Complete
resolution of the radiological signs was observed at
the tenth month of therapy. In some in vitro stu-
dies, it was found that clindamycin had a delayed
effect on T. gondii.12 In addition, it was shown that
penetration of clindamycin through the blood-brain
barrier is poor.3 Although it is not possible to
extrapolate whether CSF concentrations of clinda-
mycin are predictive of the concentrations in the
cerebral parenchyma, these findings might be the
reason for the slow resolution of this patient’s
findings.
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